Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
复制标题
DOI：
10.1080/10428194.2022.2042688
复制
发表时间：
2022-03-08
影响因子：
2.6
通讯作者：
Pratz, Keith W.
中科院分区：
文献类型：
--
作者：
Graveno, Molly E.;Carulli, Alison;Pratz, Keith W.
复发性/难治性（R/R）急性髓性白血病（AML）患者的治疗选择有限。维奈托克（VEN）联合低甲基化剂（HMA）或低剂量阿糖胞苷（LDAC）最近已被批准用于不适合强化诱导的初治患者。有限的数据可用于表征VEN组合在R/R AML中的疗效。我们回顾性分析了77例既往接受过中位1次治疗（范围0-5）的患者，这些患者接受过VEN联合治疗，用于治疗HMA单药治疗后进展的R/R AML或继发于骨髓增生异常综合征（MDS）的AML。中位总生存期（OS）为13.1个月（95%CI 9.2-15.1）。中位无进展生存期（PFS）为12个月（95% CI 8.2-15.4），中位缓解持续时间为8.9个月（95% CI 5.7-13.9）。总体缓解率（ORR）为68%，复合完全缓解（CR）和CR伴血液学不完全恢复（CRi）率为53%。VEN联合治疗对R/R AML有效，需要进一步的前瞻性研究。
Limited treatment options exist for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Venetoclax (VEN) in combination with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) has been recently approved for treatment-naive patients unfit for intensive induction. Limited data are available to characterize the efficacy of VEN combinations in R/R AML. We retrospectively analyzed 77 patients with a median of 1 prior therapy (range 0-5) treated with VEN combinations for R/R AML or AML secondary to myelodysplastic syndrome (MDS) progressing after HMA monotherapy. The median overall survival (OS) was 13.1 months (95% CI 9.2-15.1). The median progression-free survival (PFS) was 12 months (95% CI 8.2-15.4) with a median duration of response of 8.9 months (95% CI 5.7-13.9). Overall response rate (ORR) was 68% with a composite complete response (CR) and CR with incomplete hematologic recovery (CRi) rate of 53%. VEN combination therapy is efficacious in R/R AML and further prospective studies are warranted.